Oct 25, 2024
RiboX Therapeutics Announces FDA Clearance for IND Application of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation.
About RiboX
Executive Team
Dr. Weiyi Zhang
Chief Executive Officer
Dr. Yizhen Xu
Chief Medical Officer
Dr. Jennifer Kang
Head of IP & Corporate Legal
Ribox Team
